Rod and rod mediated function in patients with β-thalassemia major

Documenta Ophthalmologica

Volumn 96, Issue 4, 1998, Pages 333-346

  Jiang, Chunguang ^a   Hansen, Ronald M ^a   Gee, Beatrice E ^a   Kurth, Susan S ^a   Fulton, Anne B ^a  

^a HARVARD MEDICAL SCHOOL   (United States)

Author keywords

Electroretinogram; Iron; Scotopic; Thalassemia

Indexed keywords

DEFEROXAMINE; FERRITIN; IRON;

ADOLESCENT; ADULT; ARTICLE; BETA THALASSEMIA; BLOOD TRANSFUSION; CHELATION THERAPY; CHILD; CONTROLLED STUDY; DARK ADAPTATION; ELECTRORETINOGRAPHY; FEMALE; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; IRON OVERLOAD; MAJOR CLINICAL STUDY; MALE; PHOTORECEPTOR; PHOTOTRANSDUCTION; RETINA DISEASE; THALASSEMIA MAJOR; VISUAL THRESHOLD;

EID: 0032310611     PISSN: 00124486     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1001728512515     Document Type: Article

References (45)

1. Fosburg MT, Nathans DJ, Treatment of Cooley's anemia. Blood 1990; 76(3): 435-444.
2. Lucarelli G. et al., Marrow transplantation in patients with thalassemia responsive to iron chelation therapy. N Engl J Med 1993 329(12): 840-844.
3. Arden GB et al., Ocular changes in patients undergoing long-term desferrioxamine treatment. Br J Ophthalmol 1984; 68: 873-877.
4. Brittenham GH et al., Efficacy of deferoxamine in preventing complications of iron overload in patients with thalassemia major. N Engl J Med, 1994; 331: 567-573.
5. Gutteridge J, Richmond R. and Halliwell B. Inhibition of the iron catalyzed formation of hydroxyl radicals from superoxice and of lipid peroxidation by desferrioxamine. Biochem J, 1979. 184: 496-472.
6. Good PA et al., A model for desferrioxamine-induced retinopathy using the albino rat. Ophthalmologica, 1990. 201: 32-36.
7. Rapp L et al., Morphological and biochemical comparisons between retinal regions having differing susceptibility to photoreceptor degeneration. In 'Retinal Degeneration: Experimental and Clinical Studies' 1985: 421-437.
8. Wong V, Li A and Lee ACW, Neurophysiologic study of beta-thalassemia patients. Child Neurol, 1993. 8: 330-335.
9. Weatherall DJ, The treatment of thalassemia - slow progress and new dilemmas. N Engl J Med, 1993. 329(12): 877-879.
10. Piomelli S, Management of Cooley's anaemia. Baillier's Clin Hematol, 1993. 6(1): 287-298.
11. Cohen A et al., Vision and hearing during deferrioxamine therapy. J Ped, 1990. 117(2): 326-330.
12. Arden GB, Deferrioxamine administered intravenously by infusion causes a reduction in the electroretinogram in rabbits anaesthetized with urethane. Human Toxicol, 1986. 5: 229-236.
13. DeVirgilis S, Turco CM, MP et al., Depletion of trace elements and acute ocular toxicity induced by desferrioxamine in patients thalassemia. Arch Disease in Childhood, 1988. 63: 250-255.
14. Davies SC et al., Ocular toxicity of high-dose intravenous desferrioxamine. Lancet, 1983. 23: 181-184.
15. Lakhanpal V, Schocket SS, and Rouben J, Desferoxamine induced toxic retinal pigmentary degeneration and presumed optic neuropathy. Ophthalmol, 1984. 91: 443-451.
16. Oliveri N, et al., Visual and auditory neurotoxicity in patients receiving subcutaneous defferoxamine infusions. N Engl J Med, 1986. 314: 869-873.
17. Brueckner R, Pathological lenticular changes in animals after long-term administration of elevated doses of desferal. Helv Physiology Acta, 1967. 25: 62-77.
18. Porter JB and Huehns ER, The toxic effects of desferrioxamine. Baillier's Clin Hematol, 1989. 2(2): 459-474.
19. Gutteridge J and Halliwell B, Iron toxicity and oxygen radicals. Baillier's Clin Hematol, 1989. 2: 195-199.
20. Wise J B, Treatment of experimental siderosis bulbi, vitreous haemorrhage and corneal blood staining with desferrioxamine. Arch Ophthalmol, 1966. 75: 689-707.
21. Pugh EN Jr., and Lamb TD, Amplification and kinetics of the activation steps in phototransduction. Biochim et Biophys Acta, 1993. 1141: 111-149.
22. Dowling JE, The retina: An approachable part of the brain. 1987, Cambridge, Ma: Belknap Press.
23. Lamb TD and Pugh EN Jr., A quantitative account of the activation steps involved in phototransduction in amphibian photoreceptors. J Physiol, 1992. 449: 719-758.
24. Hood DC and Birch DG, Rod phototransduction in retinitis pigmentosa: Estimation and interpretation of parameters derived from the rod a-wave. Invest Ophthalmol Vis Sci, 1994. 35: 2948-2961.
25. Oliveri NF et al., Survival in medically treated patients with homozygous β-thalassemia. New England Journal of Medicine, 1994. 331: 574-578.
26. Birch DG and Fish GE, Rod ERGs in retinitis pigmentosa and cone-rod degeneration. Investigative Ophthalmology & Visual Science, 1987. 28: 140-150.
27. Sandberg MA, Miller S, and Berson EL, Rod electroretinograms in an elevated cyclic guanosine monophosphate-type human retinal degeneration. Invest Ophthalmol Vis Sci, 1990. 31: 2283-2287.
28. Jacobson SG et al., Phenotypes of stop codon and splice site rhodopsin mutations causing retinitis pigmentosa. Invest Ophthalmol Vis Sci, 1994. 35: 2521-2534.
29. Fulton AB and Hansen RM, ERG responses and refractive errors in patients with a history of ROP. Doc Ophthal, 1996. 91: 87-100.
30. Fulton AB and Hansen RM, Photoreceptor function in infants and children with a history of mild retinopathy of prematurity. J Opt Soc Am (A), 1996. 13: 566-571.
31. Kraft TW, Schneeweis DM, and Schnapf IL, Visual transduction in human rod photoreceptors. Journal of Physiology, 1993. 464: 747-765.
32. 2 and APB on the light induced potassium changes and the ERG b-wave of the isolated superfused retina. Vision Res, 1996. 36: 499-507.
33. Hood D and Birch D, Beta wave of the scotopic (rod) electroretinogram as a measure of the activity of human on-bipolar cells. Journal of the Optical Society of America A-Optics & Image Science, 1996. 13(3): 623-33.
34. Robson J and Frishman L, Response linearity and kinetics of the cat retina: the bipolar cell component of the dark-adapted electroretinogram. Visual Neuroscience, 1995. 12(5): 837-50.
35. Peachey NS, Alexander KR, and Fishman GA, The luminance-response function of the dark-adapted human electroretinogram. Vision Research, 1989. 29: 263-270.
36. Severns ML and Johnson M, The care and fitting of Naka-Rushton functions to electroretinographic intensity response data. Documenta Ophthalmologica, 1993. 85(2): 135-150.
37. Fulton AB et al., Temporal summation in dark adapted 10-week-old infants. Vision Res, 1991. 31: 1259-1269.
38. Fulton A, Hansen R, and Mayer L, Vision in Leber Congenital Amaurosis. Arch Ophthalmology, 1996. 114: 698-703.
39. Wetherill GB and Levitt H, Sequential estimation of points on a psychometric function. Brit J Math Stat Psychol, 1965. 18: 1-10.
40. Whitmore GA, Prediction limits for a univariate normal observation. American Statistician, 1986. 40: 141-143.
41. Berson EL et al., Natural course of retinitis pigmentosa over a three year interval. Am J Ophthalmol, 1985. 99: 240-251.
42. Breton ME, Quinn GE and Schueller AW, Development of ERG and rod phototransduction response in human infants. Invest Ophthalmol Vis Sci, 1995. 36: 1588-1602.
43. Perlman I, Relationship between the amplitude of the b-wave and the a-wave as a useful index for evaluating the electroretinogram. Brit J Ophthalmol, 1983. 67: 443-448.
44. Pall H et al., Ocular toxicity of desferrioxamine - an example of copper promoted auto-oxidative damage. Br J Ophthalmol, 1989. 73: 42-47.
45. Oliveri NF et al., Iron chelation therapy with oral deferiprone in patients with thalassemia major. N Engl J Med, 1995. 332: 918-922.